// App-Quantinova.ai

e16524 : Sequencing in metastatic castrate-resistant prostate cancer with enzalutamide in a post-chemotherapy setting.

Researchers

Presenter

  • Bruce A. Feinberg

Principal Investigators

  • Bhavik Pandya

  • Janna Radtchenko

  • David Garofalo

  • Scott Flanders

  • Bruce Brown

  • Arie Barlev

  • Menaka Bhor

Medical Centers

  • Cardinal Health, Dublin, OH

  • Astellas Pharma, Inc., Northbrook, IL

  • Cardinal Health, Dallas, TX

  • Astellas Pharma Global Development, Inc., Northbrook, IL

  • Astellas Pharma, Inc., Northbrook, IL

  • Medication, Inc., San Francisco, CA

Locations

  • United States

Companies

  • Astellas Pharma US,

  • Medivation, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Enzalutamide

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved